UTHR:NSD-United Therapeutics Corporation (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 361.4

Change

+8.60 (+2.44)%

Market Cap

USD 15.69B

Volume

0.56M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

N/A

USD 0.46B
SANE 4.17 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.36 % 0.00 %

-0.15 (0%)

N/A
CURE:AU ETFS S&P Biotech ETF 2.68 % 0.00 %

+0.15 (+0%)

USD 0.04B
SRHQ Elevation Series Trust - .. 2.36 % 0.00 %

-0.01 (0%)

N/A
FHH-F:CA First Trust AlphaDEX U.S... 2.33 % 0.00 %

N/A

CAD 0.01B
HLTH:AU VanEck Global Healthcare .. 2.15 % 0.00 %

+0.09 (+0%)

USD 0.06B
ZUH:CA BMO Equal Weight US Healt.. 1.87 % 0.39 %

+0.10 (+0%)

CAD 0.26B
DSMC ETF Series Solutions 1.77 % 0.00 %

-0.10 (0%)

N/A
JMEE JPMorgan Market Expansion.. 1.01 % 0.00 %

N/A

USD 1.42B
THNZ:XETRA L&G Global Thematic ESG E.. 0.85 % 0.00 %

-0.08 (0%)

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.82 % 0.00 %

+0.06 (+0%)

N/A
QVMM Invesco Exchange-Traded F.. 0.63 % 0.00 %

-0.02 (0%)

USD 0.32B
ETHO Amplify ETF Trust 0.00 % 0.45 %

+0.01 (+0%)

USD 0.18B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.40 (+0%)

N/A
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

+0.30 (+0%)

CAD 0.01B
FNDA Schwab Fundamental U.S. S.. 0.00 % 0.25 %

-0.01 (0%)

USD 9.04B
FXH First Trust Health Care A.. 0.00 % 0.63 %

+0.33 (+0%)

USD 1.18B
GURU Global X Guru Index ETF 0.00 % 0.75 %

-0.01 (0%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.04 (+0%)

USD 0.08B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.42 (0%)

USD 0.91B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.23 (0%)

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.05 (+0%)

CAD 0.01B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-2.85 (0%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.13 (0%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (0%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.08 (0%)

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.23 (0%)

N/A
QDVC:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.07 (0%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.82% 31% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.82% 31% F 31% F
Trailing 12 Months  
Capital Gain -19.36% 25% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.36% 25% F 26% F
Trailing 5 Years  
Capital Gain 100.87% 62% D 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.87% 62% D 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 28.85% 72% C 81% B-
Dividend Return 28.85% 72% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.05% 82% B 58% F
Risk Adjusted Return 90.02% 100% F 94% A
Market Capitalization 15.69B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector